Unknown

Dataset Information

0

Dose-dense nonpegylated liposomal Doxorubicin and docetaxel combination in breast cancer: dose-finding study.


ABSTRACT:

Background

Anthracyclines and taxanes are effective drugs in breast cancer (BC), but their toxicity profiles limit their use in combination. A dose-finding study was performed to determine maximum tolerated doses (MTDs) of nonpegylated liposomal doxorubicin (TLC-D99) and docetaxel (DTX) as a dose-dense schedule, to maintain dose intensity, and to limit toxicity, particularly cardiac.

Methods

Twenty-four patients were enrolled, 12 with metastatic BC, 5 with locally advanced BC, and 7 with early BC. An intra- and interpatient approach was planned in two sequential steps. In the first step, TLC-D99 was administered at dose levels of 40, 45, and 50 mg/m(2) plus DTX at a fixed dose of 50 mg/m(2). In the second step, TLC-D99 was administered at the dose established in the first step plus DTX at dose levels of 55, 60, and 65 mg/m(2). Every treatment cycle was delivered on day 1 every 14 days. Pegylated granulocyte colony-stimulating factor was scheduled on day 2. Dose-limiting toxicities (DLTs) were defined as G4 hematological; G3 nonhematological; ?10% or ?20% left ventricular ejection fraction (LVEF) reduction if the final value was <50% or ?50%, respectively; severe arrhythmia; and symptomatic heart failure. LVEF was evaluated by echocardiography every two cycles, and precursor brain natriuretic peptide (pBNP) and cardiac troponin I (cTnI) were monitored on days 1 and 2.

Results

Five DLTs occurred (20.8%). No cardiac event of congestive heart failure was reported; 2 events of grade 3 cardiac dysfunction (8.3%), including a ?20% LVEF reduction in 1 patient and symptomatic arrhythmia in another; 2 incidences of G4 neutropenia (8.3%); and 1 occurrence of G3 asthenia (4.2%) were reported. MTDs were not reached. The recommended doses were established as TLC-D99 50 mg/m(2) and DTX 65 mg/m(2). Cumulatively, mild (G1-G2) cardiac dysfunction was observed in 58.4% of patients: G1 cardiac arrhythmia was noted in 50%, G1-G2 general cardiac toxicity occurred in 25%, and concomitant toxicity was present in 17%. cTnI never increased. pBNP was increased in 25% and was associated with limiting arrhythmia in 4% and cardiac dysfunction in 16%.

Conclusion

Dose-dense TLC-D99 50 mg/m(2) and DTX 65 mg/m(2) can be safely administered in combination every 2 weeks for breast cancer, with the highest projected dose intensity for each drug at 25 and 32.5 mg/m(2) per week, respectively.

SUBMITTER: Ricevuto E 

PROVIDER: S-EPMC4319623 | biostudies-literature | 2015 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Dose-dense nonpegylated liposomal Doxorubicin and docetaxel combination in breast cancer: dose-finding study.

Ricevuto Enrico E   Cocciolone Valentina V   Mancini Maria M   Cannita Katia K   Romano Silvio S   Bruera Gemma G   Pelliccione Michela M   Adinolfi Maria Ilaria MI   Ciccozzi Antonietta A   Bafile Alberto A   Penco Maria M   Ficorella Corrado C  

The oncologist 20150119 2


<h4>Background</h4>Anthracyclines and taxanes are effective drugs in breast cancer (BC), but their toxicity profiles limit their use in combination. A dose-finding study was performed to determine maximum tolerated doses (MTDs) of nonpegylated liposomal doxorubicin (TLC-D99) and docetaxel (DTX) as a dose-dense schedule, to maintain dose intensity, and to limit toxicity, particularly cardiac.<h4>Methods</h4>Twenty-four patients were enrolled, 12 with metastatic BC, 5 with locally advanced BC, and  ...[more]

Similar Datasets

| S-EPMC4433508 | biostudies-literature
| S-EPMC5403877 | biostudies-literature
| S-EPMC3357161 | biostudies-literature
| S-EPMC7876584 | biostudies-literature
2011-04-22 | GSE28796 | GEO
| S-EPMC4859211 | biostudies-literature
| S-EPMC5649686 | biostudies-literature
| S-EPMC7870853 | biostudies-literature
2011-04-22 | E-GEOD-28796 | biostudies-arrayexpress
| S-ECPF-GEOD-28796 | biostudies-other